Aligos Therapeutics (NASDAQ:ALGS) Upgraded to Strong-Buy at Jefferies Financial Group

Aligos Therapeutics (NASDAQ:ALGS) was upgraded by equities research analysts at Jefferies Financial Group to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen cut shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Finally, UBS Group initiated coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Aligos Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Aligos Therapeutics Stock Up 5.6%

Shares of NASDAQ ALGS opened at $7.34 on Wednesday. Aligos Therapeutics has a 52-week low of $3.76 and a 52-week high of $13.69. The firm’s 50-day moving average price is $7.53 and its 200-day moving average price is $8.89. The company has a market cap of $45.43 million, a PE ratio of -0.85 and a beta of 2.67.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million. As a group, equities research analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. grew its holdings in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares in the last quarter. NorthCrest Asset Manangement LLC bought a new position in shares of Aligos Therapeutics during the 3rd quarter valued at approximately $98,000. Susquehanna International Group LLP bought a new position in shares of Aligos Therapeutics during the 3rd quarter valued at approximately $99,000. XTX Topco Ltd purchased a new position in shares of Aligos Therapeutics in the second quarter valued at $100,000. Finally, HRT Financial LP purchased a new position in shares of Aligos Therapeutics in the fourth quarter valued at $106,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.